摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-bromo-6-methyl-7,8-diazabicyclo[4.2.0]oct-7-ene-7,8-dioxide | 56906-22-0

中文名称
——
中文别名
——
英文名称
1-bromo-6-methyl-7,8-diazabicyclo[4.2.0]oct-7-ene-7,8-dioxide
英文别名
7,8-Diazabicyclo[4.2.0]oct-7-ene, 1-bromo-6-methyl-, 7,8-dioxide;6-bromo-1-methyl-8-oxido-8-aza-7-azoniabicyclo[4.2.0]octane 7-oxide
1-bromo-6-methyl-7,8-diazabicyclo[4.2.0]oct-7-ene-7,8-dioxide化学式
CAS
56906-22-0
化学式
C7H11BrN2O2
mdl
——
分子量
235.081
InChiKey
MQONQKXBMDYNHE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    118-120 °C
  • 沸点:
    317.4±52.0 °C(Predicted)
  • 密度:
    1.62±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    46.4
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    参考文献:
    名称:
    硫醇诱导的一氧化氮从3-卤代-3,4-二氢重氮1,2-二氧化物中释放出来。
    摘要:
    在这项工作中,我们研究了3,4-二氢重氮1,2-二氧化物(DD)的血管舒张作用和抗凝集作用背后一氧化氮(NO)释放的机理。研究中包括六种衍生物,即3-溴和3-氯-3,4,4-三甲基-DD(1a,b),3-溴和3-氯-4-甲基-3,4 -六亚甲基-DD(2a,b),3,3,4,4-四甲基-DD(3)和3-甲基-3,4-六亚甲基-DD(4),分析了它们对硫醇的反应性。发现3-溴-和3-氯-DD衍生物与硫醇反应;该反应可导致NO生成,DD 2a是反应性最高的化合物。从1a与半胱氨酸的反应中分离出的主要产物是2-(羟基氨基)-2-甲基丁-3-酮肟(5a)和2-羟基-2-甲基丁-3-酮肟(6)。DD与硫醇的反应速率取决于pH值和试剂浓度。NO释放的最大速率对应于1 mM范围内的硫醇浓度。根据反应动力学数据和分离出的产物,提出了一种反应机理。向牛主动脉内皮细胞添加2a导致强烈的NO释放,表明与内源性硫
    DOI:
    10.1021/jm960737s
  • 作为产物:
    描述:
    2-Hydroxyamino-2-methyl-cyclohexanone oxime 、 sodium hydroxide 以40%的产率得到
    参考文献:
    名称:
    VOLODARSKIJ L. B.; TIXONOVA L. A., XIMIYA GETEROTSIKL. SOEDIN. , 1975, HO 6, 748-752
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • A GNRH ANTAGONIST FOR USE IN THE TREATMENT OF A WOMEN AFFECTED WITH POLYCYSTIC OVARY SYNDROME
    申请人:Institut National de la Santé et de la Recherche Médicale
    公开号:EP3600373A1
    公开(公告)日:2020-02-05
  • [EN] A GNRH ANTAGONIST FOR USE IN THE TREATMENT OF A WOMEN AFFECTED WITH POLYCYSTIC OVARY SYNDROME<br/>[FR] ANTAGONISTE DE LA GNRH DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT D'UNE FEMME AFFECTÉE PAR LE SYNDROME DES OVAIRES POLYKYSTIQUES
    申请人:INST NAT SANTE RECH MED
    公开号:WO2018177746A1
    公开(公告)日:2018-10-04
    The present invention relates to the field of therapeutic treatment of polycystic ovary syndrome (PCOS). Polycystic ovary syndrome, PCOS, is the most common female reproductive disorder against which no therapeutic solution is available, beyond changes in the lifestyle. The inventors have now shown by using in vivo preclinical models, that individuals affected with PCOS have an abnormal elevated production of GnRH and that this elevated production of GnRH was transmitted to their offspring that also develop PCOS. Further, by examining AMH levels in a cohort of pregnant PCOS and control women, the inventors have found that AMH concentrations are significantly higher in PCOS women as compared to healthy women during the second trimester of gestation. These unexpected findings has allowed conceiving both prevention and treatment therapeutic strategies based on the administration of GnRH antagonists. Especially, the present invention relates to a gonadotropin-releasing hormone (GnRH) antagonist for its use in a woman affected with polycystic ovary syndrome (PCOS) for preventing the occurrence of PCOS in the offspring of the said woman. Even more interestingly, the present invention relates to a gonadotropin-releasing hormone (GnRH) antagonist for its use to rescue ovulation and fertility in postpuberal PCOS affected individuals.
  • Thiol-Induced Nitric Oxide Release from 3-Halogeno-3,4-dihydrodiazete 1,2-Dioxides
    作者:Igor A. Kirilyuk、Darkhan I. Utepbergenov、Dmitrii G. Mazhukin、Klaus Fechner、Katharina Mertsch、Valery V. Khramtsov、Ingolf E. Blasig、Reiner F. Haseloff
    DOI:10.1021/jm960737s
    日期:1998.3.1
    their reactivity toward thiols was analyzed. The 3-bromo- and 3-chloro-DD derivatives were found to react with thiols; this reaction can lead to NO formation, DD 2a being the most reactive compound. 2-(Hydroxyamino)-2-methylbutan-3-one oxime (5a) and 2-hydroxy-2-methylbutan-3-one oxime (6) were the main products isolated from the reaction of 1a with cysteine. Reaction rates of DD with thiols were dependent
    在这项工作中,我们研究了3,4-二氢重氮1,2-二氧化物(DD)的血管舒张作用和抗凝集作用背后一氧化氮(NO)释放的机理。研究中包括六种衍生物,即3-溴和3-氯-3,4,4-三甲基-DD(1a,b),3-溴和3-氯-4-甲基-3,4 -六亚甲基-DD(2a,b),3,3,4,4-四甲基-DD(3)和3-甲基-3,4-六亚甲基-DD(4),分析了它们对硫醇的反应性。发现3-溴-和3-氯-DD衍生物与硫醇反应;该反应可导致NO生成,DD 2a是反应性最高的化合物。从1a与半胱氨酸的反应中分离出的主要产物是2-(羟基氨基)-2-甲基丁-3-酮肟(5a)和2-羟基-2-甲基丁-3-酮肟(6)。DD与硫醇的反应速率取决于pH值和试剂浓度。NO释放的最大速率对应于1 mM范围内的硫醇浓度。根据反应动力学数据和分离出的产物,提出了一种反应机理。向牛主动脉内皮细胞添加2a导致强烈的NO释放,表明与内源性硫
  • VOLODARSKIJ L. B.; TIXONOVA L. A., XIMIYA GETEROTSIKL. SOEDIN. <KGSS-AQ>, 1975, HO 6, 748-752
    作者:VOLODARSKIJ L. B.、 TIXONOVA L. A.
    DOI:——
    日期:——
查看更多

同类化合物

1,2-Diisopropyl-1,2-diazetidin 1,2-Diazaspiro(2,5)octane, 1-methyl- 1,2-Dimethyl-1,2-diazetidin diethyl (E)-3-(chloromethylene)-1,2-diazetidine-1,2-dicarboxylate 2,3-bis(carbethoxy)-2,3-diazabicyclo<2.2.0>hex-5-ene 1,3-Dicyclohexyl-1,3-diazetidine 3-bromo-3,4,4-trimethyl-3,4-dihydrodiazete 1.2-dioxide 1,2-Diazete, 3,4-dihydro-3,3,4-trimethyl-, 1,2-dioxide 1-bromo-6-methyl-7,8-diazabicyclo[4.2.0]oct-7-ene-7,8-dioxide di-tert-butyl 3-methylene-1,2-diazetidine-1,2-dicarboxylate 4-Oxa-1,7-diazabicyclo[5.2.0]nonane 4-Bromo-3,3-dimethyl-1-oxo-1,2-diazetidin-1-ium-2-olate 1-Oxo-1,2-diazetidin-1-ium-2-olate diethyl (1RS,6SR)-7,8-diazabicyclo[4.2.0]octane-7,8-dicarboxylate diethyl 7,8-diazabicyclo[4.2.0]oct-1-ene-7,8-dicarboxylate (S)-diethyl 3-methyl-1,2-diazetidine-1,2-dicarboxylate diethyl 3-methylene-1,2-diazetidine-1,2-dicarboxylate (3R)-3,4,4-trimethyl-1-oxido-2-oxodiazetidin-2-ium-3-ol diamino (3R)-3-ethoxydiazetidine-1,2-dicarboxylate 3-ethoxy-[1,2]diazetidine-1,2-dicarboxylic acid dimethyl ester 1,2,2,3,4,4-Hexamethyl-1,3-diazetidine 1,3-Diazetidine;ethane 1,3-Diazabicyclo[1.1.0]butane [4-(Aminomethyl)-1,3-diazabicyclo[1.1.0]butan-2-yl]methanamine 2-(1,3-Diazetidin-2-yl)-1,3-diazetidine 9-Oxido-9-aza-8-azoniabicyclo[5.2.0]nonane 8-oxide (3S)-3,4,4-trimethyl-1-oxido-2-oxodiazetidin-2-ium-3-ol dimethyl (3S)-3-ethoxydiazetidine-1,2-dicarboxylate diamino (3S)-3-ethoxydiazetidine-1,2-dicarboxylate 2,4-Dithia-3,6,7-triazabicyclo[3.2.0]heptane 1,1-Dimethyldiazetidin-1-ium Diazaspiro[3.3]heptane 2-Methyl-1,2-diazaspiro[3.5]nonane 2-Thia-1,6-diazabicyclo[3.2.0]heptan-7-one 1,2-Diazabicyclo[1.1.0]butane 2-Aza-1-azoniabicyclo[1.1.0]butane 2,4-Dioxa-3,6,7-triazabicyclo[3.2.0]heptane 1-(Diazetidin-1-yl)diazetidine 2-(Diazetidin-1-yl)ethanol 1,2-Diazaspiro[3.4]octane;hydrochloride 1,2-Diazaspiro[3.4]octane 1,2-Diazaspiro[3.5]nonane-2-carboxylic acid 3,4,4-Trimethyl-1,2-dioxido-diazete-1,2-diium-3-ol 1,3-Diazetidine 1,2-Diazetidine 3-hydrazino-3,4-bis-trifluoromethyl-[1,2]diazetidine 3,4-Dihydro-3,3,4,4-tetramethyl-1,2-diazete 1,2-dioxide 1,3-dichloro-1,3-diazetidine-2,4-dione